

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FII	LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
10/016,418	11/02/2001		Gregory S. Welmaker	AM100315	8652	
25291	7590	02/25/2004		EXAM	INER	
WYETH	W CDOU		COLEMAN, BRENDA LIBBY			
PATENT LAW GROUP FIVE GIRALDA FARMS				ART UNIT	PAPER NUMBER	
MADISON, NJ 07940				1624		
				DATE MAILED: 02/25/2004	DATE MAILED: 02/25/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)	
	10/016,418	WELMAKER ET AL.	
Office Action Summary	Examiner	Art Unit	
	Brenda L. Coleman	1624	
The MAILING DATE of this communication a Period for Reply	appears on the cover sheet wi	th the correspondence address	
A SHORTENED STATUTORY PERIOD FOR REI THE MAILING DATE OF THIS COMMUNICATION - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a - If NO period for reply is specified above, the maximum statutory peri - Failure to reply within the set or extended period for reply will, by sta Any reply received by the Office later than three months after the may earned patent term adjustment. See 37 CFR 1.704(b).	N. 1.136(a). In no event, however, may a re- reply within the statutory minimum of thirt- iod will apply and will expire SIX (6) MON- tute, cause the application to become AB	eply be timely filed y (30) days will be considered timely. THS from the mailing date of this communication. ANDONED (35 U.S.C. § 133).	
Status			
1) Responsive to communication(s) filed on 20	<u> November 2003</u> .		
2a) ☐ This action is FINAL . 2b) ☑ T	his action is non-final.		
3) Since this application is in condition for allow	wance except for formal matte	ers, prosecution as to the merits is	
closed in accordance with the practice unde	er <i>Ex parte Quayle</i> , 1935 C.D	. 11, 453 O.G. 213.	
Disposition of Claims			
4) Claim(s) 1-19 is/are pending in the application	on.		
4a) Of the above claim(s) 1-12 is/are withdra	awn from consideration.		
5) Claim(s) is/are allowed.			
6)⊠ Claim(s) <u>13-19</u> is/are rejected.			
7) Claim(s) is/are objected to.			
8) Claim(s) are subject to restriction and	d/or election requirement.		
Application Papers			
9)☐ The specification is objected to by the Exam	iner.		
10) The drawing(s) filed on is/are: a) a	accepted or b) \square objected to I	by the Examiner.	
Applicant may not request that any objection to t	he drawing(s) be held in abeyan	ce. See 37 CFR 1.85(a).	
Replacement drawing sheet(s) including the corr			
11) The oath or declaration is objected to by the	Examiner. Note the attached	Office Action or form PTO-152.	
Priority under 35 U.S.C. § 119			
12) ☐ Acknowledgment is made of a claim for forei a) ☐ All b) ☐ Some * c) ☐ None of:	ign priority under 35 U.S.C. §	119(a)-(d) or (f).	
1. Certified copies of the priority docume	ents have been received.		
2. Certified copies of the priority docume	•	· ·	
3. Copies of the certified copies of the p	•	received in this National Stage	
application from the International Bure	, , , , , , , , , , , , , , , , , , , ,		
* See the attached detailed Office action for a l	ist of the certified copies not	received.	
Attachment(c)			
Attachment(s) 1) Notice of References Cited (PTO-892)	4) Interview S	ummary (PTO-413)	
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date	
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/0 Paper No(s)/Mail Date 1/14/03, 11/20/03, 1/25/03	08) 5)	formal Patent Application (PTO-152) 	

DETAILED ACTION

Claims 1-27 are pending in the application.

Election/Restrictions

1. Applicant's election with traverse of Group II in Paper dated November 20, 2003 is acknowledged. The traversal is on the ground(s) that the intermediate compounds of Claims 1, 5 and 9 are required in at least one of the process claims of Claims 13, 16 or 19 and thus a search of the process of Claim 13, 16 or 19 will also involve a search of the compounds of Claims 1, 5 and 9. The applicants additionally stated that it would not be a serious burden for the Examiner to search the intermediate compound claims of Group I while searching for the process claims of Group II. This is not found persuasive because the process of preparing the diazabenzo[cd]cyclopenta[a]azulene compounds of Claim 13, 16 and 19 is classified separately from the intermediates of Claims 1-12 which are structurally dissimilar compounds, i.e. cyclopenta[b]indole and are classified in various subclasses under class 548. If a reference for one would not be a reference for the other, then restriction is considered proper.

Thus, separate searches in the literature would be required. However, should applicant traverse on the ground that the intermediates are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Application/Control Number: 10/016,418

Art Unit: 1624

The class/subclass search on the elected invention, i.e. the process of preparing the diazabenzo[cd]cyclopenta[a]azulene compounds would be as follows: class 540, subclasses 555 and 556 which involved 221 US patents. The various classes and subclasses mentioned above represent only the degree of burden within the U.S. Patent Classification System, this does not include the search required in the prior art of journal articles and foreign patents.

The requirement is still deemed proper and is therefore made FINAL.

2. Claims 1-12 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in Paper filed November 20, 2003.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter, which the applicant regards as his invention.

- 3. Claims 13-19 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The following reason(s) apply:
- a) Claims 13, 16 and claims dependent thereon are vague and indefinite in that it is not known what is meant by "A" process for the synthesis of diazabenzo[cd]cyclopenta[a]azulene compounds of which a cyclopenta[b]indole compound is converted to a cyclopenta[b]indol-4-ylacetamide compound, where it is not known what

Application/Control Number: 10/016,418

Art Unit: 1624

reactants are present to convert a cyclopenta[b]indole compound to a cyclopenta[b]indol-4-ylacetamide compound.

- Claims 13, 16 and claims dependent thereon are vague and indefinite in b) that it is not known what is meant by "A" process for the synthesis of diazabenzo[cd]cyclopenta[a]azulene compounds of which a cyclopenta[b]indol-4ylacetamide compound is reduced to a cyclopenta[b]indol-4-yl-amine compound, where it is not known what reactants are present to reduce a cyclopenta[b]indol-4ylacetamide compound to a cyclopenta[b]indol-4-yl-amine compound.
- Claims 13, 16, 19 and claims dependent thereon are vague and indefinite in that it is not known what is meant by "A" process for the synthesis of diazabenzo[cd]cyclopenta[a]azulene compounds of which a cyclopenta[b]indol-4-yl-amine compound is cyclized to a diaza-benzo[cd]cyclopenta[a]azulene compound, where it is not known what reactants are present to cyclize a cyclopenta[b]indol-4-yl-amine compound to a diaza-benzo[cd]cyclopenta[a]azulene compound.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brenda L. Coleman whose telephone number is 571-272-0665. The examiner can normally be reached on 9:30-6:00 Monday - Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mukund Shah can be reached on 571-272-0674. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306. If you are unable to reach Dr. Shah within a 24 hour period, please contact James O. Wilson, Acting -SPE of 1624 at 571-272-0661.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Page 5

Brenda Coleman

Primary Examiner Art Unit 1624

February 22, 2004